Polares Medical SA, a clinical-stage structural heart company developing a transcatheter therapy for mitral regurgitation, has raised $50 million in a Series C financing to support the U.S. expansion of its MRace Posterior Leaflet Replacement system following strong clinical results.
The oversubscribed round included participation from DC Global Ventures, Lumination Partners, existing investors and a new strategic investor. The company said the proceeds will be used to advance clinical studies of MRace in the U.S., Europe and Australia.
Polares is targeting the large and growing population of patients suffering from mitral regurgitation, particularly those with secondary MR, a condition commonly treated with transcatheter edge-to-edge repair. While that approach has transformed treatment, anatomical complexity can limit its use in certain patients.
The MRace Posterior Leaflet Replacement system is designed to expand transcatheter treatment options across a broad spectrum of mitral anatomies, simplify the procedure and preserve future treatment pathways. The company said the device has now been implanted in more than 70 patients, with one-year data demonstrating sustained safety and efficacy.
Founded in Switzerland and with U.S. operations in California, Polares said the expanded clinical experience has validated its posterior leaflet replacement concept and generated encouraging outcomes.
KEY QUOTES:
“We believe Posterior Leaflet Replacement represents a new chapter in transcatheter mitral therapy. With over 70 patients of clinical experience and encouraging one-year data demonstrating sustained safety and efficacy, we have established a strong foundation for MRace. This financing positions us to advance the treatment paradigm for complex mitral regurgitation.”
Jacques R. Essinger, Ph.D., Chief Executive Officer, Polares Medical
“Polares is addressing one of structural heart’s largest and most important markets with a differentiated approach. The MRace system has the ability to treat a broad range of patients and widen access to mitral valve interventions worldwide.”
Min Cui, Managing Partner, DC Global Capital
